Business ❯ Pharmaceutical Industry ❯ Drug Development

Market Competition

Pricing Strategies Eli Lilly Novo Nordisk Eli Lilly vs Novo Nordisk Sales Performance Obesity Drugs Consumer Health Generic Medications Product Launches Novo Nordisk's Market Position Alternative Products Insurance Coverage Product Launch Cost Reduction Sales Projections Weight Loss Drugs Financial Deals Insurance Policies Generic Drugs Regulatory Compliance Obesity Drug Market Weight Loss Products Stock Performance

FDA Rejects Replimune’s Melanoma Virus Therapy Again for Insufficient Evidence

The decision underscores the FDA’s insistence on well‑controlled efficacy data over single‑arm results.

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA Approves Palsonify, First Once-Daily Oral Treatment for Acromegaly

FDA Approves J&J’s Inlexzo Bladder Drug-Delivery Device for BCG‑Unresponsive NMIBC

Eli Lilly’s Oral GLP-1 Pill Matches Injectables in Weight and Blood Sugar Control